BCEL - Earnings announcements

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati

SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc

Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C

SAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a virtual R&D Day on Tuesday, April 5, 2022, at 4:15 p.m. EDT, focused on the Company's preclinical pipeline programs in oncology. Presenters: John Orwin, Chief Executive OfficerTito Serafini, PhD, Chief Strategy Officer and FounderDaniel Emerling, PhD, Senior Vice President, Research and Co-FounderAmy Manning-Bog, PhD, Vice President, Translational SciencesShaun Lippow, PhD, Vice Presi

Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical activity observed in multiple tumor types and significantly associated with ATRC-101 target expression; target diagnostic validated and planning for participant selection based on target expression ATRC-101 has been well-tolerated with no dose-limiting toxicities observed Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EST SAN CARLOS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on

SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will report fourth quarter 2021 financial results and members of the company's management team will host a year-end conference call, which will include an update on progress in the ongoing ATRC-101 clinical program, on Thursday, March 3, 2022, at 4:30 p.m. EST. To access the live conference call by telephone, please dial (800) 373-6606 (Domestic) or 409-937-8918 (International). The conference

SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a webinar to present initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types on Thursday, July 29, 2021, at 8:00 a.m. ET. Conference Call and Webcast Information The live webcast, including slides, can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events